Czarnetzki 2015.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 132 adults (macrolide n = 66, placebo n = 66) Age in years (median (IQR)): macrolide: 40.5 (31 to 58), placebo: 45.0 (29 to 55) Setting: secondary care
Interventions	Indication: gastric emptying in people undergoing general anaesthesia for emergency surgery Type of macrolide: erythromycin lactobionate Route: intravenous Dose per day: 3 mg/kg Duration of treatment: 1 day Total treatment dose: 223.5 mg (mean weight in macrolide group used)
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: yes Adverse events ascertainment: participant asked + clinical examination Adverse events: data reported Antimicrobial resistance: not reported Death: not reported
Funding sources	Study supported by institutional funds from the Division of Anestesiology, Geneva University Hospitals.
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation not described.
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical‐appearing placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding of participants and staff
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts
Selective reporting (reporting bias)	Low risk	Adverse events stated as an outcome, standardised ascertainment, and adverse events reported.
Other bias	Low risk	None were identified.